TMDX Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

156.34M

+28.54%

0.389

+104.61%

171.09M

+19.2%

0.708

+1.14%

185.45M

+17.85%

0.836

-9.13%

Estimates Revision

The market is revising Upward the revenue expectations for TransMedics Group, Inc. (TMDX) for FY2025, with the revenue forecasts being adjusted by 0.31% over the past three months. During the same period, the stock price has changed by 3.24%.

Revenue Estimates for FY2025

Revise Upward

+0.31%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Up

+3.24%

In Past 3 Month

10 Analyst Rating

Wall Street analysts forecast TMDX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TMDX is 143.67 USD with a low forecast of 115.00 USD and a high forecast of 170.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

8 Buy

2 Hold

0 Sell

Strong Buy

Current: 123.010

Low

115.00

Averages

143.67

High

170.00

Current: 123.010

Low

115.00

Averages

143.67

High

170.00

Needham

Buy

maintain

$148 -> $166

2025-12-08

Reason

Needham

Price Target

$148 -> $166

2025-12-08

maintain

Buy

Reason

Needham raised the firm's price target on TransMedics to $166 from $148 and keeps a Buy rating on the shares. The SRTR - Scientific Registry of Transplant Recipients - data for October 2025 indicates that the company's transplant volumes were likely above the average monthly rate in Q3, and based on the SRTR data, the firm estimates that TransMedics had a transplant volume of 460 in October vs. its estimated average monthly transplant volume of 394 in Q3, the analyst tells investors in a research note.

Morgan Stanley

Equal Weight

maintain

$123 -> $135

2025-12-02

Reason

Morgan Stanley

Price Target

$123 -> $135

2025-12-02

maintain

Equal Weight

Reason

Morgan Stanley raised the firm's price target on TransMedics to $135 from $123 and keeps an Equal Weight rating on the shares. Going into 2026, MedTech "looks well-positioned on several fronts" as the firm thinks major product cycles and a supportive hospital spending environment, combined with trough valuations, make for "a solid industry setup," the analyst tells investors in a note for the group on the upcoming year.

Canaccord

Buy

maintain

$142 -> $147

2025-10-30

Reason

Canaccord

Price Target

$142 -> $147

2025-10-30

maintain

Buy

Reason

Canaccord raised the firm's price target on TransMedics to $147 from $142 and keeps a Buy rating on the shares. The firm said they delivered revenue in line with the firm's estimates, but slightly short of consensus which may present an interesting buying opportunity. Given the expectation for a seasonally slow and relatively in-line quarter, they believe their thesis is intact and believe any dip in the stock price creates a buying opportunity for longer-term investors,

Piper Sandler

Matt O'Brien

Overweight

downgrade

$145 -> $140

2025-10-30

Reason

Piper Sandler

Matt O'Brien

Price Target

$145 -> $140

2025-10-30

downgrade

Overweight

Reason

Piper Sandler analyst Matt O'Brien lowered the firm's price target on TransMedics to $140 from $145 and keeps an Overweight rating on the shares. The firm notes the company reported Q3 results that landed just shy of consensus on the top line but handily beat on the bottom-line. Despite the revenue performance, management raised the midpoint of its full-year sales guidance based on business momentum and the nice Q4 start seen in October. Piper thinks the FY25 sales and OM outlook is conservative and should deliver upside to end the year.

Needham

Hold

Buy

upgrade

$148

2025-10-23

Reason

Needham

Price Target

$148

2025-10-23

upgrade

Hold

Buy

Reason

Needham upgraded TransMedics to Buy from Hold with a $148 price target. Needham's transplant tracker indicates that TransMedics' U.S. sales are likely to beat consensus in Q3, the analyst tells investors in a research note. The firm also expects the company's new heart and lung clinical trials and its international expansion to become growth drivers in 2026. Meanwhile, TransMedics' margins are "increasing rapidly," which should drive upside to earnings estimates, contends the analyst. Needham thinks the company "has a significant lead in a still significantly underpenetrated market."

Evercore ISI

Outperform

initiated

$155

2025-09-16

Reason

Evercore ISI

Price Target

$155

2025-09-16

initiated

Outperform

Reason

Evercore ISI initiated coverage of TransMedics with an Outperform rating and $155 price target. There is a misunderstanding among investors that the cost of TransMedics' services are materially higher than competitive alternatives, but the firm's analysis shows total costs are similar, despite materially better patient outcomes, the analyst tells investors. The firm cites the company's "differentiated" end-to-end organ transplant offering and "impressive financial outlook" for its Outperform rating on TransMedics.

Valuation Metrics

The current forward P/E ratio for Transmedics Group Inc (TMDX.O) is 47.87, compared to its 5-year average forward P/E of -8.73. For a more detailed relative valuation and DCF analysis to assess Transmedics Group Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-8.73

Current PE

47.87

Overvalued PE

78.99

Undervalued PE

-96.45

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-4.71

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

90.63

Undervalued EV/EBITDA

-100.05

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

10.69

Current PS

0.00

Overvalued PS

16.80

Undervalued PS

4.58

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

TMDX News & Events

Events Timeline

No data

News

2.0

12-10Benzinga

Seeking a Squeeze? The 10 Most Shorted Stocks at Present

3.0

11-25CNBC

This organ transport stock is surging. Here's what the charts suggest about its potential trajectory.

6.5

11-25NASDAQ.COM

1 Growth Stock I'm Grateful For – and the Irresistible Stock I'm Investing In Based on Its Insights

People Also Watch

Frequently Asked Questions

What is Transmedics Group Inc (TMDX) stock price today?

The current price of TMDX is 123.01 USD — it has decreased -0.11 % in the last trading day.

What is Transmedics Group Inc (TMDX)'s business?

TransMedics Group, Inc. is a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure. The Company specializes in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Its Organ Care System (OCS) is a portable organ perfusion, optimization and monitoring system that utilizes its customized technology to replicate near-physiologic conditions for donor organs outside the human body. It also developed its National OCS Program (NOP), which is a turnkey solution to provide outsourced organ procurement, OCS perfusion management and transplant logistics services, to provide transplant programs in the United States. Its logistics services include aviation transportation and other coordination activities. Its NOP provides trained organ procurement surgeons, clinical specialists and transplant coordinators that provide an end-to-end clinical solution using its OCS technology.

What is the price predicton of TMDX Stock?

What is Transmedics Group Inc (TMDX)'s revenue for the last quarter?

Transmedics Group Inc revenue for the last quarter amounts to 143.82M USD, increased 32.24 % YoY.

What is Transmedics Group Inc (TMDX)'s earnings per share (EPS) for the last quarter?

Transmedics Group Inc. EPS for the last quarter amounts to 0.60 USD, increased 400.00 % YoY.

What changes have occurred in the market's expectations for Transmedics Group Inc (TMDX)'s fundamentals?

How many employees does Transmedics Group Inc (TMDX). have?

Transmedics Group Inc (TMDX) has 728 emplpoyees as of December 16 2025.

What is Transmedics Group Inc (TMDX) market cap?

Today TMDX has the market capitalization of 4.21B USD.